ReviewAsian journal of pharmaceutical sciences2022
Exosomes in cancer immunoediting and immunotherapy.
Review in Asian journal of pharmaceutical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 63 citations in OpenAlex.
- Recent progress of dendritic cell-derived exosomes in tumor immunotherapy.Investigational new drugs · 2026Review
- Exosomal bioactive molecules: molecular regulation, functional heterogeneity, and translational implications in disease diagnostics and therapeutics.Clinical and experimental medicine · 2026Review
- Exosome-based strategies and immunotherapy for skin cancer: mechanisms, challenges, and future directions.Medical oncology (Northwood, London, England) · 2026Review
- Extracellular Vesicles in Pancreatic Cancer Function and Potential Clinical Applications.OncoTargets and therapy · 2026Review
- Exosome-Based Approaches in Regenerative Medicine and Targeted Therapy for Eye Malignancies: A Comprehensive Review.Eye and brain · 2026Review
- Exosomal biomarkers and immune checkpoint inhibitors: advancements and future prospects.Cancer cell international · 2025Review
- Advances in cancer immunotherapy: historical perspectives, current developments, and future directions.Molecular cancer · 2025Review
- Article
- Transforming Medicine: Cutting-Edge Applications of Nanoscale Materials in Drug Delivery.ACS nano · 2025Review
- Emerging role of exosomes in cancer therapy: progress and challenges.Molecular cancer · 2025Review
- Exosome-Based Therapeutics in Dermatology.Biomaterials research · 2025Review
- Harnessing Tumor Cell-Derived Exosomes for Immune Rejection Management in Corneal Transplantation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis.Journal of medicinal chemistry · 2024Review
- Extracellular vesicles in nanomedicine and regenerative medicine: A review over the last decade.Bioactive materials · 2024Review
- Tumorigenic and tumoricidal properties of exosomes in cancers; a forward look.Cell communication and signaling : CCS · 2024Review
- Exosomes as Vehicles for Noncoding RNA in Modulating Inflammation: A Promising Regulatory Approach for Ischemic Stroke and Myocardial Infarction.Journal of inflammation research · 2024Review
- Exosomes: a promising avenue for cancer diagnosis beyond treatment.Frontiers in cell and developmental biology · 2024Review
- Intercellular crosstalk between cancer cells and cancer-associated fibroblasts via exosomes in gastrointestinal tumors.Frontiers in oncology · 2024Review
- Exosomes in esophageal cancer: a promising frontier for liquid biopsy in diagnosis and therapeutic monitoring.Frontiers in pharmacology · 2024Review
- Engineered exosomes-based theranostic strategy for tumor metastasis and recurrence.Asian journal of pharmaceutical sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As an important means of communication among cells, exosomes are being studied more and more widely, especially in the context of cancer immunotherapy. In the phase of tumor immunoediting, exosomes derived from tumor cells and different immune cells have complex and changeable physiological functions, because they carry different proteins and nucleic acid from the source cells. Based on the role of exosomes in the communication between different cells, cancer treatment methods are also under continuous research. This review briefly introduces the molecular composition of exosomes, which is closely related to their secretion mechanism. Subsequently, the role of exosomes encapsulating different information molecules is summarized. The role of exosomes in the three phases of tumor immunoediting is introduced in detail, and the relevant literature of exosomes in the tumor immune microenvironment is summarized by using a novel framework for extracting relevant documents. Finally, it summarizes the various exosome-based immunotherapies currently proposed, as well as the challenges and future prospects of exosomes in tumor immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.